Skip to content

A Multi-Center, Prospective, Open Label Clinical Trial to Evaluate Impact of Extended Electrocardiographic Monitoring Using MEMO Patch Plus in Patients with Acute Heart Failure

A Multi-Center, Prospective, Open Label Clinical Trial to Evaluate Impact of Extended Electrocardiographic Monitoring Using MEMO Patch Plus in Patients with Acute Heart Failure

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0008650
Enrollment
60
Registered
2023-07-27
Start date
2023-11-14
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : After voluntary written consent, the subject receives a prescription for MEMO Patch Plus while hospitalized, attaches it for up to 14 days, and returns it. At the time of discharge, a

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Male or female adults aged 19 years or older at the time of informed consent 2) Participant who voluntarily agrees to participate and signs informed consent form in the study 3) Participant with Acute Heart Failure who is hospitalized* * It is defined as hospitalization or visiting ER (Emergency Room) due to worsening symptoms and signs of Heart Failure

Exclusion criteria

Exclusion criteria: Any potential participant who meets any of the following criteria will be excluded from participating in the study. 1) Participant who does not have the ability to voluntarily decide on their decision to participate in the study 2) Participate who is admitted to ICU (Intensive Care Unit) 3) Participate diagnosed with the following the main type of arrhythmia on standard 12-lead ECG evaluated for the first time after visiting the hospital *Clinically Significant Arrhythmia is defined by the following items. A. Pause lasting more than 3 seconds B. High-degree AV Block or Complete AV Block C. Atrial fibrillation/flutter D. Supraventricular tachycardia(including atrial tachycardia and paroxysmal ventricular tachycardia) E. Ventricular tachycardia F. Ventricular fibrillation 4) Subject with a mental illness (cognitive disorder or dementia, etc.) judged by the investigator to interrupt with the compliance of the study or who is in social situation 5) Subject who has experienced allergic skin trouble to extracorporeal medical electrodes and the same preparations 6) Subject with life expectancy less than 3 months as determined by the investigator

Design outcomes

Primary

MeasureTime frame
Detection rate of clinically significant arrhythmia* *Clinically significant arrhythmia is defined as follows. A. Pause lasting more than 3 seconds B. High-degree AV Block or Complete AV Block C. Atrial fibrillation/flutter D. Supraventricular tachycardia(including atrial tachycardia and paroxysmal ventricular tachycardia) E. Ventricular tachycardia F. Ventricular fibrillation

Secondary

MeasureTime frame
1) Detection rate for other arrhythmia items identified through ECG monitoring results 2) The percentage of change in the type of clinical care according to arrhythmia diagnosis A. The percentage of anticoagulant usage/change B. The percentage of antiarrhythmic agent usage/change C. The percentage of conducting DC cardioversion D. The percentage of implantation of cardiac implantable electronic device(pacemaker, ICD, CRT etc) 3) Number and incidence of major clinical events (death, myocardial infarction, cerebral infarction, intensive care unit admission rate, re-admission after discharge) up to 3 months after discharge 4) Burden of atrial fibrillation or atrial flutter 5) The Longest duration of AF/AFL event 6) The Compliance with MEMO Patch Plus A. MEMO Patch Plus actual attached time B. Percentage of electrocardiogram that can be checked

Countries

Korea, Republic of

Contacts

Public ContactMyoungEun Kim

Asan Medical Center

kme0907asan@gmail.com+82-2-3010-1586

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026